On June 17, 2022, Caregiver Action Network CEO John Schall testified. He spoke in front of the FDA Psychopharmacologic Drugs Advisory Committee. The testimony supported approving Acadia Pharmaceuticals Inc.’s supplemental new drug application for NUPLAZID. This drug treats the hallucinations and delusions of Alzheimer’s Disease psychosis. If approved, the drug would treat these behaviors associated [...]

New Research Published: Tackling the Challenges of Getting a Timely Diagnosis for Alzheimer’s Disease